Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation The ENGAGE AF-TIMI 48 Trial

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:64

Article

Ruff, Christian T.¹  Giugliano, Robert P.¹  Braunwald, Eugene¹  Mercuri, Michele²  Curt, Valentin²  Betcher, Joshua³  Grip, Laura¹  Cange, Abby L.¹  Crompton, Andrea E.¹  Murphy, Sabina A.¹  Deenadayalu, Naveen¹  Antman, Elliott M.¹ 

[1] Brigham & Womens Hosp, Harvard Med Sch, Boston, MA 02115 USA

[2] Daiichi Sankyo Pharma Dev, Edison, NJ USA

[3] Quintiles Inc, Res Triangle Pk, NC USA

关键词: anticoagulation;    atrial fibrillation;    edoxaban;    factor Xa inhibitor;    new oral anticoagulants;    vitamin K antagonist;   

DOI  :  10.1016/j.jacc.2014.05.028

来源: Elsevier

【 摘 要 】

BACKGROUND At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vitamin K antagonist (VKA). OBJECTIVES The ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial compared once-daily edoxaban to warfarin for stroke prevention in patients with AF. An end-of-trial transition plan was developed to minimize the risks of stroke due to inadequate anticoagulation and bleeding from excessive anticoagulation during this critical period. METHODS All patients on the blinded study drug at the trial's conclusion were included in this analysis. In pre-specified analyses, stroke, bleeding, and death that occurred through 30 days after the end-of-trial visit were stratified by randomized treatment allocation and open-label anticoagulant selected post-trial. RESULTS Of the 13,642 patients taking the blinded study drug at the end of the trial, 9,304 (68.2%) were transitioned to open-label VKA and 4,258 patients (31.2%) to an NOAC. There were 21 strokes evenly distributed across the 3 randomized treatment arms: warfarin 7 (1.90%/year), edoxaban high dose 7 (1.89%/year), edoxaban low dose 7 (1.85%/year). Major bleeding was also similar across the 3 treatment arms: warfarin 11 (2.98%/year), edoxaban high dose 10 (2.69%/year), edoxaban low dose 18 (4.76%/year). In patients transitioned to VKA, 85% of patients had at least 1 INR >= 2 by day 14 after the transition and 99% by day 30. CONCLUSIONS The ENGAGE AF-TIMI 48 transition plan protected patients from an excess of thrombotic and bleeding events and should be helpful in clinical practice when patients are transitioned between oral anticoagulants. (Global Study to Assess the Safety and Effectiveness of Edoxaban [DU-176b] vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [EngageAFTIMI48]; NCT00781391) (C) 2014 by the American College of Cardiology Foundation.

【 授权许可】

Free